and a tetrapeptide-based cleavable linker. The agent is approved in the United States for treatment of HER2-positive or HER2-low metastatic breast cancer. Ado-trastuzumab emtansine is an antibody ...

Trastuzumab deruxtecan (DS-8201) is an antibody-drug conjugate composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody, a cleavable tetrapeptide-based linker, and a cytotoxic ...

Trastuzumab emtansine employs ImmunoGen's non-cleavable SMCC linker and DM1 cancer-killing agent. About ImmunoGen, Inc. ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company ...

To exert their cytotoxic effects, ADCs such as ado-trastuzumab emtansine, which have a non-cleavable (commonly a thioether) linker, must be internalised by the target cell for the antibody ...

The investigational product is an antibody-drug conjugate (ADC) comprised of the anti-HER2 monoclonal antibody trastuzumab and a cleavable ... with trastuzumab emtansine. Patients were randomly ...

Opens in a new tab or window Trastuzumab deruxtecan (Enhertu) demonstrated "unprecedented" efficacy compared with trastuzumab emtansine ... tetrapeptide-based cleavable linker, and a novel ...

In the DESTINY-Breast03 trial, trastuzumab deruxtecan reduced the risk of disease progression or death by 72% versus trastuzumab emtansine (T-DM1) (hazard ratio [HR] = 0.28; 95% confidence ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer. New England Journal of Medicine , 2025; 392 (3): 249 DOI: 10.1056/NEJMoa2406070 Cite This Page : ...